‘Withdrawal neuroleptic malignant syndrome’: a phantom explanatory cause for a fatality

Ball H , de Waal H , Craig K . An unrecognised case of withdrawal neuroleptic malignant syndrome: a case report. Med Sci Law 2009;49:298–300

Gillman PK . Neuroleptic malignant syndrome: mechanisms, interactions and causality. Mov Disord 2010;25 (12):1780–90

Gillman PK . CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol (Oxf) 2010: E-pub February 10 DOI: 10.1177/0269881109359098

Stotz M , Thummler D , Schurch M , Renggli JC , Urwyler A , Pargger H . Fulminant neuroleptic malignant syndrome after perioperative withdrawal of anti-Parkinsonian medication. Br J Anaesth 2004;93:868–71

Amore M , Zazzeri N . Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1323–34

Spivak B , Gonen N , Mester R , Averbuch E , Adlersberg S , Weizman A . Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996;11:207–9

Factor SA , Santiago A . Parkinsonism-hyperpyrexia syndrome in Parkinson's disease. In: Frucht SJ , Fahn S , eds. Movement Disorder Emergencies: Diagnosis and Treatment. Totowa, NJ: Humana Press Inc, 2005:29–40

Takubo H , Harada T , Hashimoto T , A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9(Suppl 1):S31–41

Kellam AM . The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry 1987;150:752–9

Levinson DF , Simpson GM . Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the ‘neuroleptic malignant syndrome’. Arch Gen Psychiatry 1986;43:839–48

Hill AB . The environment and disease: association or causation? Proc R Soc Med 1965;58:295–300

Doll R . Sir Austin Bradford Hill and the progress of medical science. BMJ 1992;305:1521–6

Godinho EM , Thompson AE , Bramble DJ . Neuroleptic withdrawal versus serotonergic syndrome in an 8-year-old child. J Child Adolesc Psychopharmacol 2002;12:265–70

Clarkson PM , Kearns AK , Rouzier P , Rubin R , Thompson PD . Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc 2006;38:623–7

Kuncl RW . Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009;22:506–15

Ribeyron S , Guy C , Koenig M , Cathebras P . [Olanzapine induced rhabdomyolysis and serum creatine kinase increase]. Rev Med Interne 2009;30:477–85

Capacchione JF , Muldoon SM . The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009;109:1065–9